MedWatch interview with CEO Nils Brünner on the collaboration between Scandion Oncology and Alligator Bioscience

MedWatch has interwied CEO Nils Brünner about the new and exiting reserach collaboration between Scandion Oncology og Alligator Biosciences.

The aim for this reserach project is to obtain proof-of-concept that SCO-101 in combination with the immuneoncology drug mitazalimab can lead to improved anti-cancer response.

The interview can be found here:

Svensk biotekselskab skal give Scandion Oncology fodfæste inden for immunonkologi: